Director at West Pharmaceutical (NYSE: WST) awarded 791 shares

Rhea-AI Filing Summary

Joseph Molly reported acquisition or exercise transactions in this Form 4 filing.

West Pharmaceutical Services director Molly Joseph received a grant of 791 shares of common stock as restricted stock units. The award was granted at a price of $0.00 per share, reflecting equity compensation rather than an open-market purchase. After this grant, Joseph holds a total of 4,398.187 shares of West Pharmaceutical common stock. According to the disclosure, these restricted stock units will vest in full on the date of the next annual shareholder meeting, at which point they are expected to become fully owned shares, subject to any applicable plan terms.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Joseph Molly

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	791	$0.00	--

Holdings After Transaction: Common Stock — 4,398.187 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Restricted stock units granted: 791 shares Grant price per share: $0.00 per share Total shares after transaction: 4,398.187 shares

3 metrics

Restricted stock units granted 791 shares Equity award to director Molly Joseph on 2026-05-04

Grant price per share $0.00 per share Compensation grant, not open-market purchase

Total shares after transaction 4,398.187 shares Joseph’s direct holdings following the grant

Key Terms

restricted stock units, annual shareholder meeting, Grant, award, or other acquisition

3 terms

restricted stock units financial

"These shares of restricted stock units will vest in full on the date"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

annual shareholder meeting financial

"will vest in full on the date of the next annual shareholder meeting"

A yearly gathering where a company’s owners (shareholders) and its leaders meet to review performance, approve key decisions like electing directors, and vote on issues such as executive pay or major policy changes. Think of it as an annual town hall for people who own part of the business: investors use it to ask questions, influence direction through votes, and gauge management’s plans and transparency, all of which can affect the stock’s outlook.

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Joseph Molly

(Last) (First) (Middle)

530 HERMAN O. WEST DRIVE

(Street)

EXTON PENNSYLVANIA 19341

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
WEST PHARMACEUTICAL SERVICES INC [ WST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/04/2026		A		791(1)	A	$0	4,398.187	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares of restricted stock units will vest in full on the date of the next annual shareholder meeting.

	/s/ Louis Lalli, as an agent for Molly Joseph	05/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did West Pharmaceutical (WST) director Molly Joseph receive in this insider filing?

Molly Joseph received a grant of 791 restricted stock units of West Pharmaceutical common stock. The award was made as equity compensation at $0.00 per share, increasing her direct holdings to 4,398.187 shares after the transaction.

Is the Molly Joseph transaction in West Pharmaceutical (WST) an open-market stock purchase?

No, the transaction is a grant of restricted stock units, not an open-market purchase. The filing shows 791 shares acquired at a price of $0.00 per share, indicating compensation rather than buying shares on the open market.

When will Molly Joseph’s restricted stock units in West Pharmaceutical (WST) vest?

The filing states that these restricted stock units will vest in full on the date of the next annual shareholder meeting. Once vested, the units are expected to convert into fully owned shares under the company’s equity plan terms.

How many West Pharmaceutical (WST) shares does Molly Joseph own after this grant?

Following this equity award, Molly Joseph directly holds 4,398.187 shares of West Pharmaceutical common stock. This total includes the newly granted 791 restricted stock units reported in the insider transaction disclosure.

What does the A code mean in the West Pharmaceutical (WST) insider transaction?

The transaction is coded “A”, which the filing describes as a grant, award, or other acquisition. Here it reflects 791 restricted stock units granted as compensation, rather than a standard buy or sell trade in the market.